据外媒6月17日报道，礼来（Eli Lilly）正就收购基因编辑初创公司Verve Therapeutics（纳斯达克代码：VERV）展开深入谈判，交易总额最高或达13亿美元。 据 ...

Verve Therapeutics’ stock was rallying by a record 80% on Eli Lilly’s premium purchase price for the drug-development company.

Verve's leading programs aim to deliver lifelong cardiovascular risk reduction with a single dose by targeting genes strongly linked to cardiovascular disease Lilly's established capabilities in ...

Eli Lilly to buy Verve Therapeutics for $10.50 per share, with total potential payout up to $13.50 per share. The $1.3 billion deal offers a 113% premium to Verve’s 30-day average stock price.

Lilly is acquiring an exciting new program with the agreement to buy Verve Therapeutics. Shares in Verve Therapeutics (NASDAQ ...

Shares of Verve Therapeutics soared 75% Tuesday as Eli Lilly said it would acquire the gene-editing startup. The deal values Verve at about $1.3 billion, with some of Eli Lilly's potential ...

The total potential Eli Lilly deal value represents a 115% premium to Verve’s share price at market close yesterday (16 Jun). Shares in Nasdaq-listed Verve surged to $11.03 at market open on 17 ...

Eli Lilly is taking a big swing into gene editing with a deal to buy Verve (NASDAQ:VERV) Therapeutics for up to $1.3 billion, paying $10.50 per share in cash plus a contingent right worth up to $3 ...

Key Takeaways Shares of Verve Therapeutics soared 75% Tuesday as Eli Lilly said it would acquire the gene-editing startup.The deal values Verve at about $1.3 billion, with some of Eli Lilly's ...

The acquisition aligns with Eli Lilly’s broader diversification strategy beyond its core diabetes and obesity treatment portfolio. Verve’s innovative gene-editing technology, which permanently ...

Eli Lilly agreed to acquire Verve Therapeutics for approximately $1 billion up front, adding a potential treatment for cardiovascular disease to its portfolio. Under the agreement, the ...

Summary. Verve Therapeutics announced a partnership with Eli Lilly & Co., focusing on in-vivo gene editing technology, but investors remain concerned about the FDA's clinical hold on Verve's PCSK9 ...